Acute Coronary Syndromes in Antiphospholipid Syndrome-above Suspicion: A Systematic Review

Curr Probl Cardiol. 2023 Mar;48(3):101503. doi: 10.1016/j.cpcardiol.2022.101503. Epub 2022 Nov 17.

Abstract

Antiphospholipid syndrome(APS) is an autoimmune disorder characterized clinically by vascular thrombosis and/or pregnancy morbidity, associated with persistently elevated titers of antiphospholipid antibodies on at least two measurements over 12 weeks apart. In this study, we conducted a systematic review of the literature utilizing the Pubmed platform, in order to acquire clinical information about acute coronary syndromes in patients with APS. The obtained articles were reviewed in order to register the clinical characteristics, the rate of occurrence, the prognosis and the therapeutic approach of these patients. APS should be considered in young patients with acute myocardial infarction, even in patients with normal coronary arteries. The pharmaceutical approach is mainly based on the vitamin K antagonists, and in certain occasions aspirin, without any definite guidelines on the subject. Further randomized clinical trials are imperative for a better understanding of the particular characteristics of this group of patients, so that a more complete therapeutic approach to be obtained.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Acute Coronary Syndrome* / diagnosis
  • Acute Coronary Syndrome* / drug therapy
  • Acute Coronary Syndrome* / etiology
  • Antibodies, Antiphospholipid / therapeutic use
  • Anticoagulants / therapeutic use
  • Antiphospholipid Syndrome* / complications
  • Antiphospholipid Syndrome* / diagnosis
  • Antiphospholipid Syndrome* / drug therapy
  • Female
  • Humans
  • Pregnancy
  • Thrombosis* / drug therapy

Substances

  • Antibodies, Antiphospholipid
  • Anticoagulants